What is it about?
A mixture of antibodies against EGFR, HER2 and HER3 prevent resistant to Osimertinib due to EGFR C797S mutation, and moreover synergise with sub-optimal dose of Osimertinib to inhibit EGFR T790M Non-Small Cell Lung Cancers (NSCLC).
Featured Image
Read the Original
This page is a summary of: An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors, EMBO Molecular Medicine, December 2017, EMBO,
DOI: 10.15252/emmm.201708076.
You can read the full text:
Contributors
The following have contributed to this page
